Chemistry:Elafibranor

From HandWiki
Short description: Chemical compound
Elafibranor
Elafibranor.svg
Clinical data
Other namesGFT505, SureCN815512
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H24O4S
Molar mass384.49 g·mol−1
3D model (JSmol)

Elafibranor (INN,[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[3][4][5]

Elafibranor is a dual PPARα/δ agonist.[6][7]

See also

References

  1. "Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism". Diabetes Care 34 (9): 2008–14. September 2011. doi:10.2337/dc11-0093. PMID 21816979. 
  2. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74". World Health Organization. p. 10. https://www.who.int/medicines/publications/druginformation/innlists/74_PrePub_INN_Recommended_List_Report.pdf. 
  3. "Advanced Compound Status" (Press release). Genfit. Archived from the original on 2013-04-11.
  4. "GFT505 Broadens Its Therapeutic Potential" (PDF) (Press release). Archived (PDF) from the original on 10 July 2021. Retrieved 31 Mar 2013.
  5. "GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes". Expert Opinion on Investigational Drugs 23 (10): 1441–8. October 2014. doi:10.1517/13543784.2014.954034. PMID 25164277. 
  6. US Patent No. 7655641 "96 dpi image of original patent USPTO 7655641". http://www.google.com/patents/US7655641.pdf. 
  7. Vázquez-Carrera, M. (2012). "GFT-505". Drugs of the Future 37 (8): 555–559. doi:10.1358/dof.2012.037.08.1835977. http://www.biomdl.com/wp-content/uploads/2013/03/GFT505_DrugFut2012.8P555.pdf. [yes|permanent dead link|dead link}}]

External links